Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Evoke Pharma's Shares Outstanding (Weighted Average) rose 8268.74% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 8268.74%. This contributed to the annual value of $1.9 million for FY2024, which is 58390.5% up from last year.
  • Per Evoke Pharma's latest filing, its Shares Outstanding (Weighted Average) stood at $2.6 million for Q3 2025, which was up 8268.74% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's Shares Outstanding (Weighted Average) ranged from a high of $31.2 million in Q1 2021 and a low of $278558.0 during Q2 2023
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $2.6 million (2025), whereas its average is $3.6 million.
  • As far as peak fluctuations go, Evoke Pharma's Shares Outstanding (Weighted Average) tumbled by 9166.76% in 2023, and later skyrocketed by 58390.5% in 2024.
  • Quarter analysis of 5 years shows Evoke Pharma's Shares Outstanding (Weighted Average) stood at $2.7 million in 2021, then increased by 17.21% to $3.1 million in 2022, then crashed by 91.14% to $278558.0 in 2023, then skyrocketed by 583.9% to $1.9 million in 2024, then soared by 34.24% to $2.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $2.6 million for Q3 2025, versus $2.6 million for Q2 2025 and $2.5 million for Q1 2025.